Carmat - Edison Group

Carmat (PAR: ALCAR)

Currency in -

Last close As at 21/09/2023

-8.61

▲ −0.08 (−0.92%)

Market capitalisation

EUR195m

Overview
Price performance
Financials
Research
Sector insights
Thematics

Carmat is developing a biocompatible, artificial heart to satisfy the lack of donor hearts available for terminal heart failure patients. The development process combines the expertise of a wide range of technical and medical experts.

Latest Insights

View More

Healthcare |
edison tv

10.02.22

Carmat: Edison Open House Healthcare 2022

Healthcare |
Update

20.09.21

Carmat — Implantation momentum

Healthcare |
edison tv

03.02.21

Carmat – Edison Open House interview

Healthcare |
edison tv

12.01.21

Carmat – executive interview with Stéphane Piat

Sector

Healthcare

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	(2.4)	(21.8)	(17.4)
Relative	(7.4)	(25.3)	(27.4)
52 week high/low	€14.8/€8.0

Financials

Edison Investment Research is terminating coverage on Carmat (ALCAR). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2020A	0.0	N/A	(38.7)	(285.32)	N/A	N/A
2021A	2.2	N/A	(61.9)	(402.00)	N/A	N/A
2022E	N/A	N/A	N/A	N/A	N/A	N/A
2023E	N/A	N/A	N/A	N/A	N/A	N/A

Research

Healthcare

Update

Carmat — Update 15 July 2016

Healthcare

Update

Carmat — Update 5 May 2016

Update

Healthcare

15.07.16

Carmat — Update 15 July 2016

Update

Healthcare

05.05.16

Carmat — Update 5 May 2016

Further insights

insight

Healthcare

23.08.19

Total Artificial Hearts

Analyst of the week

Soo Romanoff

Managing Director - Head of Content, Healthcare

sromanoff@edisongroup.com 020 3077 5700

Read latest

cell DNA double helix

thematic

Healthcare

20.12.22

Cell and gene therapies

thematic

Healthcare

28.11.22

Drug delivery platforms

thematic

Healthcare

07.11.22

Oncology ABCs (part three) – thinking outside the box in women’s cancer

thematic

Healthcare

01.11.22

Neuroscience comeback

thematic

Consumer

05.10.22

IPO apocalypse

thematic

Healthcare

03.10.22

Oncology ABCs (part two) – vaccines: niche no longer

thematic

TMT

10.08.22

ESG, moving beyond the box tick

thematic

Healthcare

01.07.22

Oncology ABCs (part one) – a small-cap biopharma prospectus series

thematic

Healthcare

26.04.22

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

thematic

Healthcare

10.11.21

Artificial intelligence in drug discovery

thematic

Healthcare

27.07.21

Biosynthesis – Taking the cannabinoid market to new heights

thematic

Healthcare

01.02.21

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

thematic

Healthcare

30.10.19

Edison Exhibits- antibiotic development

thematic

Healthcare

17.07.19

The next wave in AMD

thematic

Healthcare

18.06.19

The A-B-T of biosimilars- Explaining contemporary life science issues

thematic

Healthcare

10.06.19

Cannabinoid Therapies- The coming retail wave

thematic

Healthcare

22.05.19

Cannabinoid Therapies- Therapeutics turning a corner

thematic

Healthcare

08.04.19

Trial outcomes and value – Explaining contemporary clinical trial issues

thematic

Healthcare

04.03.19

Drug pricing – Market access and reimbursement

thematic

Healthcare

29.01.19

The diagnostics sector

thematic

Healthcare

21.06.17

ASCO 2017

thematic

Consumer

11.11.14

Deutsche Börse Eigenkapitalforum 2014 Research Guide

thematic

Healthcare

05.03.14

Edison healthcare quarterly: A boost for allergy immunotherapy

thematic

Healthcare

04.03.14

ASX Spotlight Conference – London, 6 March 2014

thematic

Healthcare

01.03.13

ASX Small to Mid Caps Conference – London, 7 March 2013

thematic

Healthcare

07.12.12

Edison healthcare quarterly: Boom times for US biotech

thematic

Healthcare

30.08.12

Edison healthcare quarterly: Crisis? What crisis?

thematic

Healthcare

28.05.12

Edison healthcare quarterly: How to please some of the people some of the time